Fasting blood samples were collected from 83 patients with histologically proven breast cancer and analysed for plasma glucagon, serum immunoreactive tumour necrosis factor (TNFα), insulin, glucose, growth hormone, Cortisol and TSH. Samples from patients with known diabetes mellitus or thyroid disease, and those on parenteral nutrition or with evidence of infection were excluded as were patients who had a history of weight loss through dieting or who were anorexic.
Fasting plasma glucagon, serum Cortisol and immunoreactive TNFα concentrations in patients with stage IV breast cancer who had developed weight loss were significantly higher than those in patients with stage IV disease who had not developed weight loss. There were no significant differences in the fasting serum concentrations of insulin, glucose, growth hormone and TSH between the two patient groups.
The association between weight loss in stage IV breast cancer and increased concentrations of plasma glucagon, serum Cortisol and TNFα suggests a possible role for these hormonal factors in the development of cancer cachexia.
De WysWD. Anorexia as a general effect of cancer. Cancer1979; 43: 2013–19.
6.
WesdorpRICKrauseRvon MeyenfeldtMF. Cancer cachexia and its nutritional implications. Br J Surg1983; 70: 352–5.
7.
BrennanMF. Uncomplicated starvation versus cancer cachexia. Cancer Res1977; 37: 2359–64.
8.
HolroydeCPGabvizdaTGPutnamRCPaulPReichardGA. Altered glucose metabolism in metastatic carcinoma. Cancer Res1975; 35: 3710–14.
9.
JasaniBDonaldsonLJRatcliffeJGSokhiGS. Mechanism of impaired glucose tolerance in patients with neoplasia. Cancer Res1978; 38: 287–92.
10.
ScheinPSKisnerDHallerDBlecherMHamashM. Cachexia of malignancy. Potential role of insulin in nutritional management. Cancer1979; 43: 2070–6.
11.
CostaGLylesKUllrichL. Effects of human and experimental cancer on the conversion of 14C tri palmitin to 14CO2. Cancer1976; 38: 1259–65.
12.
WaterhouseCJeanpretreNKeilsonJ. Gluconeogenesis from alanine in patients with progressive malignant disease. Cancer Res1979; 39: 1968–72.
13.
SymrengTLarssonJSchildtBWetlerforsJ. Nutritional assessment reflects muscle energy metabolism in gastric carcinoma. Ann Surg1983; 198: 146–50.
14.
HarrisV. In: JaffeBMBehrmanHR, eds. Methods of Hormone Radioimmunoassays. New York: Academic Press, 1979: 643.
15.
JorensenKR. Evaluation of the double antibody radioimmunoassay of insulin and the determination of insulin in plasma and urine in normal subjects. Acta Endocrinol1969; 60: 327–51.
16.
RoseDPBerkeBCohenLA. Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay. Hormone Metab Res1988; 20: 49–53.
17.
Riad-FahmyDReadGFGaskellSJDyasJHindawiR. A simple direct radioimmunoassay for plasma Cortisol featuring a (125-I) radioligand and a solid-phase separation technique. Clin Chem1979; 25: 665–8.
18.
PatersonNBiggartEMChapmanRSBeastallGH. Evaluation of a time-resolved immunofluorometric assay for serum thyroid stimulating hormone. Ann Clin Biochem1985; 22: 606–11.
19.
CornbleetPJGochmanN. Incorrect least square regression coefficients in method comparison analysis. Clin Chem1979; 25: 432–8.
HawkerF. Endocrine changes in the critically ill. Br J Hosp Med1988; 39: 278–88.
23.
KaplanSANogeredaSCS. Effects of Cortisol on amino acids in skeletal muscle and plasma. Endocrinology1963; 72: 267–72.
24.
WarrenRSDonnerDBStarnesHFBrennanMF. Modulation of endogenous hormone action by recombinant human tumour necrosis factor. Proc Natl Acad Sci1987; 84: 8619–22.
25.
WarrenRSStarnesHFGabriloveJLOettgenHFBrennanMF. The acute metabolic effects of tumour necrosis factor administration in humans. Arch Surg1987; 122: 1396–1400.
26.
TraceyKJLowryJSFFaheyJDCachectin/tumour necrosis factor induces lethal shock and stress hormone response in the dog. Surg Gynecol Obstet1987; 164: 415–22.
27.
DinarelloCACannonTGWolffSMTumour necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med1986; 163: 1433–50.
28.
OliffADefeo-JonesDBoyerMTumours secreting human TNF/cachectin induce cachexia in mice. Cell1987; 50: 555–63.
29.
ShermanMLSpriggsDRJArthurKAImamuraKFreiEKufeDW. Recombinant human tumour necrosis factor administered as a five day continuous infusion in cancer patients: phase 1 toxicity and effects on lipid metabolism. J Clin Oncol1988; 6: 344–50.
30.
TeppoAMMauryCP. Radioimmunoassay of tumour necrosis factor in serum. Clin Chem1987; 33: 2024–7.
31.
BalkwillFOsborneRBurkeFEvidence for tumour necrosis factor/cachectin production in cancer. Lancet1987; ii: 1229–32.
32.
AderkaDFisherSLevoYHoltmanHHahnTWallachD. Cachectin/tumour necrosis factor production by cancer patients (Letter). Lancet1985; ii: 1190.
33.
SocherSHMartinezDCraigJBKuhnGOliffA. Tumour necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst1988; 80: 595–8.
34.
WaageAEspevickTLamvikJ. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol1986; 24: 739–43.
35.
SelbyPJHobbsSVinerCTumour necrosis factor in man: Clinical and biological observations. Br J Cancer1987; 56: 803–9.
36.
SelbyPJHobbsSVinerCJacksonESmithIEMcElwainTJ. Endogenous tumour necrosis factor in cancer patients (letter). Lancet1988; i: 483.
37.
SempleCG. Hormonal changes in non-endocrine disease. Br Med J1986; 293: 1049–53.
38.
GerichJEKaramJHForshamPH. Stimulation of glucagon secretion by epinephrine in man. J Clin Endocrinol Metab1973; 37: 479–81.
39.
YoungJBLandsbergL.Adrenergic influence on peripheral hormone secretion. In: KunosG ed. Adrenoreceptors and Catecholamine Action; part B. New York: John Wiley & Sons, 1983: 157–217.
40.
FichterMMPirkeKMHolsboerF. Weight loss causes neuroendocrine disturbances. Experimental study in healthy starving subjects. Psychiatry Research1986; 17: 61–72.
